Given the adverse cardiovascular-related events seen in COVID-19, blockade of CCR2 could potentially reduce these adverse outcomes by decreasing the amount of circulating and infection site accumulation of inflammatory monocytes and other myeloid populations [79,81,88,89]. The gene discussed is CCR2; the disease is COVID-19.